{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:35:36Z","timestamp":1761741336154,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"vor","delay-in-days":180,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2017]]},"DOI":"10.6061\/clinics\/2017(06)08","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T11:01:40Z","timestamp":1497697300000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study"],"prefix":"10.1016","volume":"72","author":[{"given":"Luciana Azevedo","family":"Callefi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane Alves","family":"Villela-Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"de Barros Tenore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimas","family":"Carna\u00faba-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique S\u00e9rgio Moraes","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo de Tarso A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Cancella","family":"Nabuco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Guimar\u00e3es","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Cardoso Gomes","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Roberto Abr\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"de Lourdes Candolo Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana Gama Florencio","family":"Chach\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalgisa","family":"de Souza Paiva Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Porto","family":"de Macedo Bisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Reis","family":"\u00c1lvares-Da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00e2nia","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Alexandra Pontes","family":"Ivantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"de Mello Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C\u00e1ssia Jacintho","family":"Mendes-Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.6061\/clinics\/2017(06)08_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"year":"2016","series-title":"Guidelines for the screening care and treatment of persons with chronic hepatitis C infection","key":"10.6061\/clinics\/2017(06)08_bib2"},{"issue":"1 Suppl","key":"10.6061\/clinics\/2017(06)08_bib3","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"13","key":"10.6061\/clinics\/2017(06)08_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"9286","key":"10.6061\/clinics\/2017(06)08_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.6061\/clinics\/2017(06)08_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.6061\/clinics\/2017(06)08_bib7","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.6061\/clinics\/2017(06)08_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.6061\/clinics\/2017(06)08_bib9","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.6061\/clinics\/2017(06)08_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"year":"2016","series-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","author":"American Association for the Study of Liver Diseases","key":"10.6061\/clinics\/2017(06)08_bib11"},{"issue":"Suplemento 1","key":"10.6061\/clinics\/2017(06)08_bib12","first-page":"52","article-title":"Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, Aids e Hepatites Virais. Protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite viral C e coinfec\u00e7\u00f5es: manejo do paciente infectado cronicamente pelo gen\u00f3tipo 1 do HCV e fibrose avan\u00e7ada","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2013","journal-title":"Bras\u00edlia"},{"issue":"Suplemento 2","key":"10.6061\/clinics\/2017(06)08_bib13","article-title":"Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, Aids e Hepatites Virais. Protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite viral C e coinfec\u00e7\u00f5es: gen\u00f3tipo 1 do HCV e fibrose avan\u00e7ada","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2013","journal-title":"Bras\u00edlia"},{"issue":"2","key":"10.6061\/clinics\/2017(06)08_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"2","key":"10.6061\/clinics\/2017(06)08_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"10.6061\/clinics\/2017(06)08_bib16","unstructured":"European Medicines Agency. Guideline for good clinical practice. London, 2002."},{"issue":"2","key":"10.6061\/clinics\/2017(06)08_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"year":"2004","series-title":"Table for grading the severity of adult and pediatric adverse events","author":"DAIDS (Division of AIDS)","key":"10.6061\/clinics\/2017(06)08_bib18"},{"year":"2011","series-title":"Prescribing information","author":"Victrelis (boceprevir)","key":"10.6061\/clinics\/2017(06)08_bib19"},{"year":"2013","series-title":"Prescribing information","author":"Olysio (simeprevir)","key":"10.6061\/clinics\/2017(06)08_bib20"},{"issue":"6","key":"10.6061\/clinics\/2017(06)08_bib21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1128\/JCM.01300-08","article-title":"Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification","volume":"47","author":"Chevaliez","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.6061\/clinics\/2017(06)08_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-0034-1399383","article-title":"Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort","volume":"53","author":"Mauss","year":"2015","journal-title":"Z Gastroenterol"},{"issue":"1","key":"10.6061\/clinics\/2017(06)08_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12546","article-title":"Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort","volume":"39","author":"Backus","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.6061\/clinics\/2017(06)08_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/apt.13095","article-title":"Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir","volume":"41","author":"Sterling","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.6061\/clinics\/2017(06)08_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jvh.12375","article-title":"Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings","volume":"22","author":"Butt","year":"2015","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.6061\/clinics\/2017(06)08_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10620-015-3621-0","article-title":"Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir","volume":"60","author":"Vo","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.6061\/clinics\/2017(06)08_bib27","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/liv.12861","article-title":"Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy","volume":"35","author":"Al Marzooqi","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"10.6061\/clinics\/2017(06)08_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.12656","article-title":"Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis","volume":"35","author":"Calleja","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"10.6061\/clinics\/2017(06)08_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"H\u00e9zode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.6061\/clinics\/2017(06)08_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12985-015-0261-0","article-title":"First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort","volume":"12","author":"Werner","year":"2015","journal-title":"Virol J"},{"issue":"4","key":"10.6061\/clinics\/2017(06)08_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1574887111666151217123222","article-title":"Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based &ldquo;triple therapy&rdquo; experience in southern Italy","volume":"11","author":"Morisco","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"10.6061\/clinics\/2017(06)08_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-230X-14-87","article-title":"Safety and efficacy of protease inhibitor based combination therapy in a single-center &ldquo;real-life&rdquo; cohort of 110 patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"Wehmeyer","year":"2014","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.6061\/clinics\/2017(06)08_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET","volume":"62","author":"Gordon","year":"2015","journal-title":"J Hepatol"},{"issue":"7","key":"10.6061\/clinics\/2017(06)08_bib34","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165300","article-title":"Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors","volume":"49","author":"Miotto","year":"2016","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"10.6061\/clinics\/2017(06)08_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0197-2456(99)00054-9","article-title":"Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia","volume":"21","author":"De Amici","year":"2000","journal-title":"Control Clin Trials"},{"author":"Brasil. Minist\u00e9rio da Sa\u00fade","key":"10.6061\/clinics\/2017(06)08_bib36"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222012273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222012273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:00:14Z","timestamp":1761721214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222012273"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322017000600378&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5463255\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"alternative-id":["S1807593222012273"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2017(06)08","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2017(06)08","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}